Format

Send to

Choose Destination
See comment in PubMed Commons below
Patient Prefer Adherence. 2008 Feb 2;2:323-32.

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes.

Author information

1
Scripps Whittier Diabetes Institute, La Jolla, CA, USA.

Abstract

The progressive nature of type 2 diabetes poses challenges in the clinic: treatment must be continually reviewed and adjusted in response to the patient's changing pathophysiology. Ultimately, insulin replacement therapy will be necessary as the physiological insulin response is compromised. The modern basal insulin analog insulin detemir has been the subject of several clinical trials and observational studies in type 2 diabetes. Compared with NPH insulin, insulin detemir offers an improved balance between achieving current glycemic targets with acceptable tolerability. Insulin detemir also has a unique weight-sparing effect which is associated with body mass index, and this may be a particular advantage to obese patients with type 2 diabetes. This review summarizes data from key clinical studies of insulin detemir, and also provides insights from observational studies.

KEYWORDS:

basal insulin; insulin detemir; modern analog; type 2 diabetes mellitus

PMID:
19920979
PMCID:
PMC2770411
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center